HCW Biologics arranges up to $10 million in debt financing
The company said the funds will support a Phase 1 alopecia areata study of HCW9302 through its planned dose-finding readout.
SEC filing
Latest
Thursday, November 5
Genprex poster links TUSC2 gene therapy to cellular aging-resilience pathways
Genprex said translational data from Reqorsa-treated lung cancer patients show gene expression shifts tied to cellular repair, presented at a November 2026 gerontology conference.
SEC filing
InMed completes name change to Mentari, 1-for-10 consolidation, discloses Series A preferred terms
Following the November 4, 2026 shareholder vote, the company filed amended articles creating convertible preferred shares tied to the pending Mentari merger.
SEC filing (2)
Entrada reports Q3 2026 results, DMD trials advance across multiple cohorts
The company said cash and securities of $193 million should fund operations into the fourth quarter of 2027 as several Duchenne trial readouts near.
SEC filing
Agios pushes back mitapivat sickle cell decision to February 2027
FDA extended the PDUFA goal date by three months after classifying Agios's response on a potential REMS as a major amendment.
SEC filing
Intellia reports Q3 2026 results, cites progress toward lonvo-z launch and nex-z Phase 3 enrollment
Intellia said it remains on track for a March 10, 2027 PDUFA date for lonvo-z and completed enrollment in its MAGNITUDE-2 Phase 3 trial in ATTRv-PN.
SEC filing
Avalo Therapeutics sets up $200 million at-the-market stock sale with Jefferies
The company ended its TD Cowen sales agreement the same day it signed a new ATM facility with Jefferies for up to $200 million in shares.
SEC filing
Lipocine reports Q3 2026 results, highlights BLOOM study launch for LPCN 1154
The company started its Phase 3 BLOOM trial in postpartum depression in September 2026 and reported $28.5 million in cash as of November 4, 2026.
SEC filing
Processa details Vidya deal progress and new leadership in stockholder letter
Processa Pharmaceuticals issued a November 5, 2026 letter to stockholders outlining its I&I pipeline strategy, financing runway, and executive additions following the Vidya Therapeutics acquisition.
SEC filing
Disc Medicine files $189.9 million stock offering after APOLLO Phase 3 win in EPP
Disc Medicine registered a new at-the-market equity program with TD Cowen as it prepares an NDA resubmission for bitopertin following positive Phase 3 results.
SEC filing (2)
Agenus reports Q3 2026 results, first BOT+BAL marketing nods, ROBBIN Phase 3 on track
Armenia granted the first marketing authorizations for botensilimab and balstilimab as Agenus advances its global Phase 3 ROBBIN trial toward first patient enrollment in early 2027.
SEC filing
Avalo Therapeutics files $200 million at-the-market stock offering with Jefferies
The prospectus supplement, dated November 5, 2026, lets Avalo sell shares through Jefferies over time to fund development of its lead HS drug candidate.
SEC filing
J&J posts new Phase 3 prostate cancer trial for JNJ-101556143; updates nine other registry records
NeOnc posts Q3 results, confirms positive Phase 2a data for NEO100 ahead of SNO
The company reported a narrower net loss, a $15 million raise and preferred stock redemption, and said updated NEO100 and NEO212 data will be shown at SNO on November 13.
SEC filing (2)
Tenax details LEVEL-2 protocol changes and Type C meeting after LEVEL miss
Tenax Therapeutics reported third-quarter 2026 results and outlined a predictive enrichment strategy for its LEVEL-2 trial following completed statistical analysis of the failed LEVEL study.
SEC filing
Dogwood Therapeutics reports Q3 2026 results, Halneuron Phase 2b data due in November
The company completed enrollment in its chemotherapy neuropathy trial and closed a $5 million private placement to fund Phase 3 preparation.
SEC filing
Dyne reports Q3 2026 results as z-rostudirsen BLA review continues toward January 2027 decision
FDA review of the Duchenne therapy carries a PDUFA date of January 21, 2027, while Dyne also reported new one-year DM1 data and $1.134 billion in cash.
SEC filing
Annovis Bio prices $21 million stock and warrant offering amid NYSE deficiency
The company finalized terms for a 19 million share offering at $1.00 per share after disclosing an NYSE capitalization shortfall and under $3 million in cash.
SEC filing (3)
New SWITCH trial registered pitting apixaban against warfarin in HeartMate 3 patients
ARS Pharma posts Q3 2026 results, highlights neffy share gains and CSU trial timeline
The company reported $37.7 million in third-quarter revenue and said interim Phase 2b data for its chronic urticaria candidate ARS-2 are due in early 2027.
SEC filing
Innate Pharma updates pipeline timelines in Q3 2026 report
Innate Pharma reported progress on its Nectin-4 ADC, lacutamab and monalizumab programs alongside a cash position of €96.8 million as of September 30, 2026.
SEC filing
Akebia reports Q3 2026 results as Vafseo patient count grows and VOICE, VOCAL data land
Vafseo use rose 140% year over year while Akebia highlighted positive VOICE and VOCAL trial results and a new ebribafusp alfa basket trial ahead of a 2027 TDAPA access change.
SEC filing
Prenetics' IM8 partners with Authentic Brands Group on Care Bears wellness brand
The 10-year exclusive global deal will have IM8 operate a new Care Bears-branded vitamin line, with Authentic also becoming a strategic shareholder in Prenetics.
SEC filing
Lexicon completes SONATA-HCM enrollment, eyes ZYNQUISTA resubmission in Q1 2027
Lexicon reported overenrollment in its Phase 3 hypertrophic cardiomyopathy trial and said safety data from a third-party study support plans to resubmit its diabetes drug application.
SEC filing
Amylyx reports positive LUCIDITY Phase 3 data for avexitide, raises $545 million
Amylyx said its Phase 3 trial of avexitide in post-bariatric hypoglycemia hit its primary endpoint, keeping a planned FDA filing by the end of 2026 on track.
SEC filing (2)
Latigo reports Q3 2026 results, names new CEO, adds opioid arm to Phase 3 trial
Latigo said its Phase 3 bunionectomy and safety trials of onzotrigine remain on track for 2027 topline data as Todd Smith succeeds Nima Farzan as CEO.
SEC filing (2)
Certara narrows 2026 revenue growth outlook as software revenue grows 11% in third quarter
Certara reported third quarter 2026 results on November 5, 2026, narrowed its full-year revenue growth range to 2% to 3%, and named Grant Peterson as Chief Product Officer effective November 2.
SEC filing
Conexeu Sciences files two Form D notices for stock issued to consultants
The Nevada biotechnology company reported two small equity sales tied to consulting payments, dated October 28 and October 29, 2026.
SEC filing (2)
Alnylam authorizes $1 billion stock buyback, announces commercial chief's departure
Alnylam's board approved a new $1 billion repurchase program as the company's chief commercialization officer plans to leave in December 2026.
SEC filing
Avalo reports Q3 2026 results, plans Phase 3 start for abdakibart in HS in H1 2027
Avalo said it expects FDA feedback by year-end 2026 and plans to begin a registrational Phase 3 program for abdakibart in hidradenitis suppurativa in the first half of 2027.
SEC filing
Shattuck Labs starts Phase 2b Crohn's trial for SL-325, plans HS study
The company reported third-quarter 2026 results showing a new Crohn's disease trial underway, a hidradenitis suppurativa study planned for the fourth quarter, and cash extending into 2029.
SEC filing
Filana clears FDA hold, sets early 2027 start for TSC epilepsy trial screening
Filana Therapeutics said patient screening for its Phase 2a simufilam study in TSC-related epilepsy is expected to begin by the first quarter of 2027 after the FDA lifted a clinical hold in September 2026.
SEC filing
Celldex reports Q3 2026 results, confirms 2027 BLA plan for barzolvolimab in CSU
Celldex says Phase 3 CSU trials met all endpoints and the enrolling cold urticaria study continues, with cash of $650.3 million seen funding operations into 2028.
SEC filing
Longeveron director Ursula Ungaro resigns from board, effective immediately
Ungaro stepped down from Longeveron's board and all its committees on November 1, 2026, citing personal health reasons.
SEC filing
Vericel raises 2026 revenue guidance after third-quarter growth of 26%
The company posted record quarterly revenue and MACI sales, lifted its full-year outlook, and said it is on track for a potential 2027 U.K. MACI launch.
SEC filing
Aclaris reports Q3 2026 results, positive ATI-052 data, and 2029 cash runway
The company reaffirmed upcoming bosakitug and modzatinib milestones and said it expects cash to last through the first half of 2029.
SEC filing
Korro Bio starts dosing in KRRO-121 trial, faces Novo Nordisk termination
Korro reported dosing of healthy volunteers in its ANCHOR trial and preclinical data for KRRO-111, while disclosing Novo Nordisk's move to terminate their collaboration agreement effective February 1, 2027.
SEC filing
Novavax earns $125M Sanofi milestone, raises 2026 revenue outlook
Novavax said Sanofi's Phase 3 flu-COVID combination vaccine trial start in Europe triggered a $125 million payment, as the company lifted its full-year revenue framework.
SEC filing
Lantheus reports Q3 2026 results, gains two approvals amid pending Curium merger
FDA clearances for TAUKLARIFY and BRAVNETSA arrive as Lantheus moves toward its announced $8 billion acquisition by Curium.
SEC filing
Prestige Consumer Healthcare trims fiscal 2027 outlook on Clear Eyes supply issue
The company cited manufacturing variability at its Pillar5 facility for lowering guidance even as Q2 revenue rose 22.7% on recent acquisitions.
SEC filing
Cognition Therapeutics advances zervimesine toward Phase 3 in DLB, faces Nasdaq bid price notice
The company reported Q3 2026 results, said it aligned with FDA on endpoints for a planned DLB registrational study, and disclosed a Nasdaq minimum bid price deficiency letter.
SEC filing
Karyopharm to be delisted from Nasdaq following Chapter 11 filing
Nasdaq told Karyopharm Therapeutics its stock will be delisted after the company's bankruptcy petitions, with trading suspended November 11, 2026.
SEC filing
REGENXBIO reports Q3 2026 results, confirms Duchenne BLA and wet AMD data timelines
The company said it remains on track for a Q1 2027 RGX-202 BLA submission and expects topline sura-vec wet AMD data in Q4 2026, while cash stood at $251.0 million.
SEC filing
Traws Pharma files Form D for up to $50 million equity facility
The biotech, formerly Onconova Therapeutics, registered a committed equity line under a Rule 506(b) exemption with one investor to date.
SEC filing
Climb Bio reports Q3 2026 results, dosing underway in IgAN Phase 2 trial
Climb Bio started dosing in its NAVIGATE-2 Phase 2 trial of CLYM116 and reported new budoprutug data, with cash runway now guided into the second half of 2028.
SEC filing
Cartesian reports Q3 2026 results, AURORA Phase 3 data due in 1Q27
Cartesian said its Phase 3 AURORA trial of Descartes-08 in myasthenia gravis remains on track for a 1Q27 readout, with a BLA filing planned for mid-2027.
SEC filing
Zoetis posts Q3 2026 results, narrows revenue guidance, raises EPS outlook
Zoetis reported third-quarter revenue of $2.4 billion, down 1%, while flagging pipeline approvals including Convenia RTU for Dogs and an EUA for Simparica Trio against screwworm.
SEC filing
Korsana reports Q3 2026 results, advances KRSA-028 toward the clinic
The company said it expects Phase 1 healthy volunteer data for its lead Alzheimer's candidate in mid-2027, with proof-of-concept patient data by year-end 2027 or early 2028.
SEC filing
Keros reports Q3 2026 results, dosing start in DMD trial and new bone program
Keros dosed its first Duchenne muscular dystrophy patient on rinvatercept and nominated KER-206 for further study, while projecting cash into the second half of 2028.
SEC filing